Anavex Life Sciences Corp (AVXL)

[seventhwave]

I feel the same way (caution: I'm a regular joe with no training in bio/pharm.) I've always felt that the delay in release of PK/PD results is to collect as much more longitudinal data to make the dataset as rich as possible to make your case. This is even more pertinent if you observe each progressive dataset to head in the right direction as you adapt the protocol. There is appreciable dispersion among the 25 patients and it needs to be overcome using time and any adaptation of treatment. The statistical crunching is obviously not the time impediment. I do believe 'underdosed' and '+ve response to dose escalation' mean you have completed draft runs on data. You get only one shot at proving to your peers/investors and you want to take your best shot. I think we are close as it appears to me, Missling is showing up at more and more conferences this year compared to last and he always sounds so confident. If he shows stability for 1.5yrs, it is more likely to create shock and awe. The longer the dataset the greater the suggestion of a 'cure' possibly.